Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial.
Váldodahkkit: | MacMahon, S, Rodgers, A, Collins, R, Farrell, B |
---|---|
Materiálatiipa: | Journal article |
Giella: | English |
Almmustuhtton: |
1994
|
Geahča maid
-
ANTIPLATELET THERAPY TO PREVENT THROMBOSIS AFTER HIP FRACTURE - REPLY
Dahkki: Macmahon, S, et al.
Almmustuhtton: (1995) -
The pulmonary embolism prevention (PEP) trial: Effects of low-dose aspirin on major vascular events in patients with hip fracture
Dahkki: Prentice, C, et al.
Almmustuhtton: (1999) -
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement
Dahkki: Kyung Won Kim, et al.
Almmustuhtton: (2021-01-01) -
Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration.
Dahkki: Collins, R, et al.
Almmustuhtton: (1994) -
A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial
Dahkki: de Haan RJ, et al.
Almmustuhtton: (2010-05-01)